Dr. Prather will give a 20-minute overview of Pluristem, detailing its clinical plans, product portfolio and strategic direction.

Mr. Zami Aberman, Pluristem's President & CEO, stated: "We are pleased to have been invited to the Rodman & Renshaw Conference where we will be able to showcase Pluristem and present our unique, proprietary 3D expansion process of our placental derived PLX cells, targeted at a variety of indications. We will give animal trial results, which demonstrate the potential value for our PLX cells to treat millions of patients suffering from peripheral artery disease (PAD), inflammatory bowel disease (IBD), and multiple sclerosis (MS).